Ocular Neuropathies

INGENOtyping agreement signed

Published in Gene Therapy Weekly, May 15th, 2003

Ingenium Pharmaceuticals AG and the Molecular Genetics Laboratory of the University Eye Hospital of Tuebingen announced a collaboration in which Ingenium will develop, using its INGENOtyping technology platform, animal models with defined gene alterations.

The focus of the collaboration will be genes relating to eye diseases. No financial terms were disclosed.

"Our research focuses on the elucidation of the pathophysiology of ocular neuropathies, such as glaucoma, by targeting genes that are known to be implicated in these diseases," commented professor Bernd Wissinger, PhD, Group Leader at the Molecular Genetics Laboratory of the Tuebingen...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry